CMS Cameron McKenna Nabarro Olswang LLP | United Kingdom | 30 Sep 2011
Mr Justice Floyd has granted an application for an expedited trial in favour of Teva, in circumstances in which, if Teva succeeds in invalidating Warner-Lambert’s patent, Teva may obtain an advantage over other generic manufacturers of the drug atorvastatin, marketed by Warner-Lambert as Lipitor, one of the world’s most successful drugs with an annual turnover exceeding £350 million.